Lactobacillus iners is a bacterium that lives in the human vagina and stands apart from every other vaginal Lactobacillus species in ways that have confused researchers for years. It is technically a member of the same genus as the well-studied “good bacteria” that dominate a healthy vaginal environment, yet it behaves differently enough that scientists now describe it as sitting at the crossroads of vaginal health and disease. Found in both perfectly healthy women and in those with bacterial vaginosis, L. iners resists the simple label of friend or foe, and that ambiguity is exactly what makes it so important to understand.
How L. iners Differs from Other Vaginal Lactobacilli
The vagina is typically home to a community dominated by one of a handful of Lactobacillus species, most commonly L. crispatus, L. gasseri, L. jensenii, or L. iners. For decades, researchers lumped them together under the assumption that any Lactobacillus was a sign of a healthy vaginal environment. L. iners challenged that idea once its genome was sequenced. It has the smallest genome of any known Lactobacillus, just 1.3 million base pairs on a single chromosome, suggesting it has shed large numbers of genes over evolutionary time while picking up others through horizontal gene transfer to survive specifically in the vagina.1PubMed Central. At the crossroads of vaginal health and disease, the genome sequence of Lactobacillus iners AB-1
That stripped-down genome has real consequences. L. iners does not grow on the standard laboratory agar used to culture other lactobacilli, which is one reason it went unrecognized for so long. It produces only limited amounts of hydrogen peroxide, a compound other vaginal Lactobacillus species generate to help keep harmful bacteria in check.2PubMed. Lactobacillus iners, the unusual suspect And its metabolic quirks extend to how it acidifies its surroundings, which turns out to be a critical distinction.
Why the Type of Acid Matters
All vaginal lactobacilli produce lactic acid, and the resulting low pH is one of the vagina’s main defenses against pathogens. But lactic acid comes in two mirror-image forms, D-lactic acid and L-lactic acid, and these are not interchangeable when it comes to protection. Species like L. crispatus and L. gasseri produce both forms. L. iners produces only L-lactic acid.3PLOS ONE. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review The D form appears to offer stronger defense against infections ascending into the upper reproductive tract, though research on this point is still in early stages. The practical upshot is that a vaginal community dominated by L. iners can maintain a reasonably low pH but may still leave gaps in the antimicrobial shield that L. crispatus would provide.
Inerolysin, the Toxin No One Expected
Perhaps the most unsettling discovery about L. iners is that it produces a pore-forming toxin called inerolysin. This was unexpected because lactobacilli are generally regarded as harmless or beneficial. Inerolysin belongs to a family of cholesterol-dependent cytolysins, the same broad class as toxins made by well-known pathogens. Clinical strains of L. iners produce inerolysin during normal growth, and the toxin punches holes in epithelial cell membranes. It is activated by reducing agents and inhibited by free cholesterol, and it works across the acidic pH range found in the vagina, from about 4.5 to 6.0, while becoming inactive at neutral pH.4PubMed Central. Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners
Laboratory experiments comparing inerolysin to vaginolysin, the toxin produced by the BV-associated bacterium Gardnerella vaginalis, revealed an interesting pattern. At a low pH typical of a healthy vagina, inerolysin caused far more membrane damage than vaginolysin. At neutral pH, the pattern reversed, and vaginolysin was more destructive.5Scientific Reports. Inerolysin and vaginolysin, the cytolysins implicated in vaginal dysbiosis, differently impair molecular integrity of phospholipid membranes This means L. iners could be doing low-level damage to vaginal epithelial cells even when the environment appears healthy by other measures. At concentrations too low to kill cells outright, inerolysin still triggers stress-signaling pathways and compromises cell integrity. Researchers suspect this contributes to the weakened barrier function seen when L. iners dominates.
The Immune Picture
When researchers exposed human vaginal epithelial cells to different Lactobacillus species, L. iners triggered pattern-recognition receptor signaling, the innate alarm system cells use to detect potential threats. Yet it did not increase mucin expression or cause a spike in the inflammatory signals interleukin-6 and interleukin-8.6The Journal of Infectious Diseases. Bacteria in the Vaginal Microbiome Alter the Innate Immune Response and Barrier Properties of the Human Vaginal Epithelia in a Species-Specific Manner In contrast, treatment that successfully displaced L. iners with L. crispatus lowered the inflammatory marker IL-1α and reduced a biomarker of epithelial barrier disruption called soluble E-cadherin.7The Lancet Microbe. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial So L. iners seems to occupy an immunological middle ground: it does not provoke the full-blown inflammation associated with BV-causing bacteria, but it does not provide the calming, barrier-strengthening effects of L. crispatus either.
Links to Bacterial Vaginosis and STIs
A systematic review synthesizing multiple studies concluded that L. iners is a transitional species, one that tends to colonize after the vaginal environment has been disturbed and offers less protection against dysbiosis, sexually transmitted infections, and adverse pregnancy outcomes compared to L. crispatus.8PubMed Central. Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review A meta-analysis specifically comparing L. iners-dominated and L. crispatus-dominated communities found that the former was associated with higher rates of BV and Chlamydia trachomatis infection.9PubMed Central. Epidemiologic Evidence on the Role of Lactobacillus iners in Sexually Transmitted Infections and Bacterial Vaginosis: A Series of Systematic Reviews and Meta-Analyses
A case-control study in Dutch women quantified part of this risk: women whose vaginal communities were dominated by L. iners had roughly two and a half times the odds of testing positive for chlamydia compared to those dominated by L. crispatus.10PubMed Central. Lactobacillus iners-dominated vaginal microbiota is associated with increased susceptibility to Chlamydia trachomatis infection in Dutch women, a case control study The direction of causality is not entirely settled. It is possible that L. iners dominance creates an environment where pathogens establish more easily, or that both L. iners dominance and infection susceptibility are downstream effects of the same underlying shifts in the vaginal ecosystem. But the association is consistent enough across studies that researchers take it seriously.
Pregnancy Outcomes
The stakes get higher during pregnancy. A study following pregnant women found that those whose vaginal microbiota was dominated by L. iners at 16 weeks of gestation had significantly higher rates of both short cervix and preterm birth before 34 weeks, with a positive predictive value of about 69% for preterm delivery.11PubMed Central. The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk This is a single study rather than a definitive finding, but it aligns with the broader pattern: L. iners dominance is associated with conditions that clinicians worry about, even though it is not typically considered a pathogen in its own right.
In a study of pregnant women’s vaginal bacteria, L. iners was detected nearly as often as L. crispatus but tended to dominate at higher relative abundances when it was present. Interestingly, L. iners abundance did not correlate with the abundance of several BV-associated organisms, including Gardnerella vaginalis and Prevotella, making its role harder to pin down as simply “enabling bad bacteria.”12PubMed. Influence of Lactobacillus crispatus, Lactobacillus iners and Gardnerella vaginalis on bacterial vaginal composition in pregnant women
Who Carries L. iners
Nearly everyone. L. iners is present across all ethnic and geographic groups studied, but the degree to which it dominates varies. In a diverse cohort of women of African, Asian, and European ancestries, L. iners-dominant communities were the most common single community type, found in about a quarter of participants.13PubMed Central. Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries A study of healthy Italian women found L. iners at a prevalence of 98%, making it by far the most common vaginal Lactobacillus in that population, with an average relative abundance of 40%. The authors noted that this challenges the assumption, drawn largely from North American studies, that L. iners dominance is inherently concerning.14PubMed Central. Lactobacillus iners dominates the vaginal microbiota of healthy Italian women of reproductive age
Behavioral and demographic factors also play a role. In a Brazilian cohort, L. iners-dominant communities were more common in women with two or more sexual partners and in those with Candida detected on vaginal smears, while condom use and higher educational attainment were inversely associated with L. iners dominance.15Sexually Transmitted Infections. Characteristics associated with Lactobacillus iners-dominated vaginal microbiota These associations do not prove that specific behaviors cause L. iners to take over; they more likely reflect a web of factors influencing the vaginal ecosystem simultaneously.
Not All L. iners Strains Are Equal
One reason the debate about L. iners has been so hard to resolve is that researchers were, until recently, treating it as a single entity. Strain-level analysis is starting to reveal that some L. iners strains behave quite differently from others. In a study of Chinese pregnant women, strains of L. iners isolated from women with BV formed significantly more biofilm than strains from healthy women.16npj Biofilms and Microbiomes. Metagenomic analysis reveals the novel role of vaginal Lactobacillus iners in Chinese healthy pregnant women Biofilm formation is important because bacteria embedded in biofilms are harder for the immune system and antibiotics to reach. If some strains build thick biofilms while others do not, that could explain why L. iners sometimes coexists peacefully with healthy vaginal communities and other times seems to facilitate disease.
Similarly, one study found that higher L. iners abundance in women being treated for BV was actually associated with cure rather than treatment failure, and that L. iners strains could inhibit the growth of Gardnerella vaginalis and Fannyhessea vaginae in laboratory experiments.17PubMed Central. Vaginal Lactobacillus iners abundance is associated with outcome in antibiotic treatment of bacterial vaginosis and capable of inhibiting Gardnerella This is a sharp contrast to the broader pattern of L. iners being associated with worse outcomes, and it underscores that the species label alone does not tell the whole story. The field is moving toward a more nuanced view in which strain identity, gene expression, and the surrounding microbial community all matter.
Therapeutic Approaches Targeting L. iners
If the goal is to shift a vaginal community away from L. iners dominance and toward L. crispatus, there are a few strategies under investigation. The most clinically advanced is the use of a live biotherapeutic called LACTIN-V, a formulation of L. crispatus CTV-05 applied vaginally after standard BV treatment with antibiotics. In a randomized trial, LACTIN-V led to a sustained increase in L. crispatus and L. gasseri abundance that persisted 13 weeks after treatment ended, along with reduced inflammation and improved epithelial barrier markers.7The Lancet Microbe. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial The idea is that flooding the environment with a more protective species can crowd out L. iners and BV-associated bacteria simultaneously.
Another approach exploits a metabolic vulnerability. L. iners cannot make the amino acid cysteine on its own, unlike L. crispatus, and it has a very limited toolkit for importing cysteine from its surroundings. Researchers showed that drugs blocking cystine uptake selectively inhibited L. iners growth in lab cultures without harming L. crispatus, raising the possibility of treatments that starve L. iners while leaving beneficial species intact.18PubMed Central. Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation
A third line of research involves bacteriocins, small antimicrobial peptides produced by other bacteria. Scientists identified a set of peptides from L. gasseri that selectively kill L. iners at very low concentrations. All 21 L. iners strains tested were inhibited, while fewer than 20% of L. crispatus, L. jensenii, or L. gasseri strains were affected. When combined with the antibiotic metronidazole, which is the standard treatment for BV, the bacteriocins killed both L. iners and Gardnerella vaginalis in mixed cultures.19PubMed Central. Novel Selective Inhibition of Lactobacillus iners by Lactobacillus-Derived Bacteriocins None of these targeted approaches have reached clinical use yet, but the fact that L. iners has metabolic and structural weaknesses not shared by other vaginal lactobacilli gives drug developers something to work with.
L. iners After Menopause
The vaginal microbiome changes dramatically after menopause as estrogen levels drop and the environment becomes less hospitable to lactobacilli in general. Local estrogen therapy is one of the most common treatments for the symptoms that follow, collectively called genitourinary syndrome of menopause. A study of postmenopausal women found that those who started treatment with higher L. iners abundance were less likely to respond well to local estrogen. Each tenfold increase in baseline L. iners abundance was associated with an 18% lower probability of treatment response, and women in the highest third of L. iners abundance had about 29% lower odds of responding compared to those in the lowest third.20PubMed Central. Vaginal Lactobacillus iners Abundance Predicts Response to Local Estrogen Therapy in Postmenopausal Women with Genitourinary Syndrome of Menopause If this finding holds up in larger studies, baseline microbiome testing could eventually help clinicians predict which patients need additional or different interventions beyond estrogen alone.
The postmenopausal context also adds a layer to the broader question of what L. iners is “doing.” In reproductive-age women, L. iners may be a transitional colonizer that moves in when conditions shift. In postmenopausal women, where the overall bacterial landscape is already sparse, L. iners dominance may signal a fundamentally different starting ecosystem, one that estrogen therapy alone cannot easily reshape into a L. crispatus-dominated state. This is speculative, but it fits the emerging pattern that L. iners is best understood not as inherently harmful or helpful but as a marker of an ecosystem teetering between states, and the direction it tips depends on context the species label cannot capture on its own.